Medizinische Universität Graz - Research portal
Navigation/Search
- Researchers
- Institutions
- Projects
- Publications
- Partners
- Sponsors
- Equipment
- Knowhow
- Fields of Research
"Faces" of the day:
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
von, Lewinski, D; Herold, L; Bachl, E; Bugger, H; Glantschnig, T; Kolesnik, E; Verheyen, N; Benedikt, M; Wallner, M; von, Lewinski, F; Schmidt, A; Harb, S; Ablasser, K; Sacherer, M; Scherr, D; Manninger-Wünscher, M; Pätzold, S; Gollmer, J; Zirlik, A; Toth, GG.
Outcomes of ECLS-SHOCK Eligibility Criteria Applied to a Real-World Cohort.
J Clin Med. 2023; 12(22):
Doi: 10.3390/jcm12226988
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- von Lewinski Dirk
- Co-authors Med Uni Graz
- Ablasser Klemens
- Benedikt Martin
- Bugger Heiko Matthias
- Glantschnig Theresa
- Gollmer Johannes
- Harb Stefan
- Kolesnik Ewald
- Manninger-Wünscher Martin
- Pätzold Sascha
- Sacherer Michael
- Scherr Daniel
- Schmidt Albrecht
- Toth-Gayor Gabor
- Verheyen Nicolas Dominik
- von Lewinski Friederike
- Wallner Markus
- Zirlik Andreas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Cardiogenic shock (CS) exhibits high (~50%) in-hospital mortality. The recently published Extracorporeal life Support in Cardiogenic Shock (ECLS-SHOCK) trial demonstrated the neutral effects of the use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) on all-cause death, as well as on all secondary outcomes in subjects presenting with myocardial-infarction (MI)-related CS. Here, we compared ECLS-SHOCK eligibility criteria with a real-world cohort of CS patients. METHODS AND RESULTS: ECLS-SHOCK eligibility criteria were applied to a prospective single-center CS registry (the PREPARE CS registry) consisting of 557 patients who were consecutively admitted to the catheterization laboratory (cath lab) of the Medical University of Graz, Austria, due to CS (SCAI C-E). Overall use of mechanical circulatory support (MCS) in this cohort was 19%. Sixty-nine percent of the entire cohort had MI-related CS, 38% of whom would have met ECLS-SHOCK eligibility criteria, thus representing only 27% of the PREPARE CS registry. Exclusion from the ECLS-SHOCK trial was based on patients with initial lactate values below 3 mmol/L (n = 168; 43.6%), aged over 80 years (n = 65; 16.9%), and with a duration of cardiopulmonary resuscitation (CPR) exceeding 45 min (n = 22; 5.7%). The 30-day mortality of patients of the PREPARE CS registry who met the ECLS-SHOCK eligibility criteria was 57.0%, compared to 48.4% of patients in the ECLS-SHOCK trial. The patients' baseline characteristics, however, differed considerably with respect to type of infarction, age, and gender. CONCLUSIONS: In a real-world cohort of patients with MI-related CS, only 38% of patients met the eligibility criteria of the ECLS-SHOCK trial. Thus, the impact of the use of VA-ECMO on outcome parameters in MI-related CS, as observed in the ECLS-SHOCK trial, may differ in a more heterogeneous real-world CS population of the PREPARE CS registry.
- Find related publications in this database (Keywords)
- cardiogenic shock
- myocardial infarction
- mechanical support
- VA-ECMO
- mortality
- lactate